Compare ASC & SGP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASC | SGP |
|---|---|---|
| Founded | 2010 | 2019 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 751.7M | 799.4M |
| IPO Year | 2013 | 2026 |
| Metric | ASC | SGP |
|---|---|---|
| Price | $20.13 | $23.92 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $22.50 | ★ $44.00 |
| AVG Volume (30 Days) | ★ 624.6K | 122.6K |
| Earning Date | 11-04-2026 | 11-10-2026 |
| Dividend Yield | ★ 1.56% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $16.60 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.31 | $17.06 |
| 52 Week High | $20.12 | $32.44 |
| Indicator | ASC | SGP |
|---|---|---|
| Relative Strength Index (RSI) | 65.10 | 40.58 |
| Support Level | $16.91 | $20.95 |
| Resistance Level | $20.03 | $25.83 |
| Average True Range (ATR) | 0.62 | 1.38 |
| MACD | 0.10 | -0.28 |
| Stochastic Oscillator | 95.26 | 24.21 |
Ardmore Shipping Corp provides seaborne transportation of petroleum products and chemicals world-wide to oil majors, national oil companies, oil and chemical traders, and chemical companies, with its modern, fuel-efficient fleet of mid-size product and chemical tankers. The company markets its services directly to its customers and commercial pool operators and charters its vessels to them through a combination of spot, commercial pooling, and time-charter arrangements. The majority of its revenue is generated from spot voyages, which typically last less than three months.
SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.